Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/19/18vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City. A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com. vTv Therapeuti... 
Printer Friendly Version
11/08/18vTv Therapeutics Announces Third Quarter 2018 Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 8, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events. “We continue to believe in the therapeutic potential of azeliragon and are committed to finding the optimal development pathway forward for the program,” said Steve Holcombe, chief executive officer, vTv... 
Printer Friendly Version
10/29/18vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 29, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Common Stock on The Nasdaq Capital Market. The Company’s securities will be transf... 
Printer Friendly Version
10/24/18vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 24, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of ora... 
Printer Friendly Version
10/16/18vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 16, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheime... 
Printer Friendly Version
08/30/18vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 30, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held Se... 
Printer Friendly Version
08/03/18vTv Therapeutics Announces Second Quarter 2018 Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 3, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events. “Since our announcement regarding the topline results from Part B of the STEADFAST Study, we have continued to analyze the results from Parts A and B and are encouraged by our findings,” said Steve Holcombe, ... 
Printer Friendly Version
06/22/18vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific ... 
Printer Friendly Version
06/12/18vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental ... 
Printer Friendly Version
05/31/18vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
HIGH POINT, N.C.--(BUSINESS WIRE)--May 31, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Mal... 
Printer Friendly Version
05/15/18vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights
HIGH POINT, N.C.--(BUSINESS WIRE)--May 15, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31, 2018. “We continue to make progress on all of our major programs,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “While our initial readout of the results of our STEADFAST Part A Study was not what we had hoped for, we are pleased with the results... 
Printer Friendly Version
05/09/18vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June
Subgroup of Mild Alzheimer’s Patients in Part A of Phase 3 STEADFAST Study Demonstrated Positive Benefit HIGH POINT, N.C.--(BUSINESS WIRE)--May 9, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identifie... 
Printer Friendly Version
04/09/18vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes as measured by the Alzheimer's Disease A... 
Printer Friendly Version
03/22/18vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study, being conducted with support from JDRF, ... 
Printer Friendly Version
02/27/18vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 27, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017. “We made tremendous progress across the spectrum of our Alzheimer’s and diabetes programs this past year, and look forward to continuing this momentum in 2018 as we anticipate reporting topline results in Apr... 
Printer Friendly Version